Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Agilent (A)

Tipranks - Tipranks - Thu Jan 8, 12:32PM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amylyx Pharmaceuticals Inc (AMLX – Research Report), Agilent (A – Research Report) and Protagonist Therapeutics (PTGX – Research Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Amylyx Pharmaceuticals Inc (AMLX)

In a report issued on January 5, Geoff Meacham from Citi maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $20.00. The company’s shares closed last Wednesday at $11.69.

According to TipRanks.com, Meacham is a 4-star analyst with an average return of 7.5% and a 55.3% success rate. Meacham covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Protagonist Therapeutics, and Kiniksa Pharmaceuticals. ;'>

Currently, the analyst consensus on Amylyx Pharmaceuticals Inc is a Strong Buy with an average price target of $20.14.

See Insiders’ Hot Stocks on TipRanks >>

Agilent (A)

TD Cowen analyst Daniel Brennan maintained a Buy rating on Agilent today. The company’s shares closed last Wednesday at $145.86.

According to TipRanks.com, Brennan is a 5-star analyst with an average return of 23.2% and a 58.0% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Adaptive Biotechnologies, and Nautilus Biotechnolgy. ;'>

Agilent has an analyst consensus of Strong Buy, with a price target consensus of $167.08, which is a 13.2% upside from current levels. In a report issued on January 5, Evercore ISI also upgraded the stock to Buy with a $160.00 price target.

Protagonist Therapeutics (PTGX)

Citi analyst Joanne Wuensch maintained a Buy rating on Protagonist Therapeutics on January 5 and set a price target of $115.00. The company’s shares closed last Wednesday at $80.27.

According to TipRanks.com, Wuensch is a 4-star analyst with an average return of 5.6% and a 60.5% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Establishment Labs Holdings, and Bausch + Lomb Corporation. ;'>

Protagonist Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $94.54, which is a 14.9% upside from current levels. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $86.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).